Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized placebo-controlled study of inhaled MK-5475 in adults with pulmonary hypertension associated with COPD
MOH_2023-01-17_012273Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of frespaciguat in Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH) and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Efficacy. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
frespaciguat
03
Conditions
Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2023-01-17_012273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-17_012273.